| Assessment Status |
NCPE Assessment Process Complete |
| HTA ID |
- |
| Drug |
Dabrafeib |
| Brand |
Tafinlar® |
| Indication |
For the treatment of adult patients with unresectable or Metastic Melanoma with a BRAF V600 mutation. |
| Rapid review commissioned |
11/09/2013 |
| Rapid review completed |
02/10/2013 |
| Rapid review outcome |
Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant |
03/12/2013 |
| NCPE assessment completed |
24/06/2014 |
| NCPE assessment outcome |
The NCPE considers dabrafenib (Tafinlar®) to be cost effective compared to vemurafenib. |
